Satpathy, Shankha http://orcid.org/0000-0002-6040-4854
Jaehnig, Eric J. http://orcid.org/0000-0001-9618-6011
Krug, Karsten
Kim, Beom-Jun
Saltzman, Alexander B.
Chan, Doug W.
Holloway, Kimberly R.
Anurag, Meenakshi
Huang, Chen
Singh, Purba
Gao, Ari
Namai, Noel
Dou, Yongchao
Wen, Bo http://orcid.org/0000-0003-2261-3150
Vasaikar, Suhas V. http://orcid.org/0000-0001-9763-3899
Mutch, David
Watson, Mark A.
Ma, Cynthia
Ademuyiwa, Foluso O.
Rimawi, Mothaffar F. http://orcid.org/0000-0002-4284-5656
Schiff, Rachel http://orcid.org/0000-0003-1696-5213
Hoog, Jeremy
Jacobs, Samuel
Malovannaya, Anna http://orcid.org/0000-0003-2953-6485
Hyslop, Terry
Clauser, Karl R.
Mani, D. R.
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Miles, George
Zhang, Bing http://orcid.org/0000-0001-8676-2425
Gillette, Michael A.
Carr, Steven A. http://orcid.org/0000-0002-7203-4299
Ellis, Matthew J. http://orcid.org/0000-0002-8467-8534
Article History
Received: 13 September 2019
Accepted: 31 December 2019
First Online: 27 January 2020
Competing interests
: M.J.E. reports Ownership and Royalties associated with Bioclassifier LLC though sales by Nanostring LLC for the Prosigna breast cancer prognostic test. He also reports Ad Hoc consulting for AstraZenica, Novartis, Sermonix, Abbvie, Pfizer. Foluso Ademuyiwa reports institutional research grants from Seattle Genetics, Abbvie, Pfizer, Immunomedics, Neoimmunetech, RNA diagnostics, polyphor and consulting income from immunomedics, Astra Zeneca, Eisai, Best doctors, Advanced Medical. D.M. reports speaking and consulting income from Clovis and AstraZeneca. C.M. reports research funding from Puma Biotechnology, Pfizer and Eisai and consulting fees from Novartis, Pfizer and Eli Lilly. C.P. reports ownership and royalties associated with Bioclassifier LLC though sales by Nanostring LLC for the Prosigna breast cancer prognostic test. M.R. reports consulting income from Genentech/Roche, Daiichi, Macrogenics and Novartis. Reseach Funding from GSK and Pfizer. R.S. reports institutional research grants from AstraZeneca, GlaxoSmithKline, Gilead Sciences, and PUMA Biotechnology. She also reports a previous Ad Hoc consulting for Eli Lilly and current consulting/advisory income from Macrogenics. B.Z. reports research funding from Bristol-Myers Squibb. The remaining authors declare no competing interests.